CatalystMarker
← board

VREOD

distress 2/10 · well-funded / low risk
$9.78-2%today-58% from 52w high
vireogrowth.com520 employeesFounded 2004Minneapolis, MNDrug Manufacturers - Specialty & Generic
Revenue
$106M
Liquidity
$145M
Runway
Shares 1y

Price & events

-39.5% over 6M
$9.56$13.36$17.15Jan 26Apr 26Jul 2654k
CatalystRating changeDilutionFinancingdashed = today
-2.4%
1D
-1.7%
1W
-13.0%
1M
-20.7%
3M
-42.4%
6M
-26.1%
1Y
2Y
5Y
-43.3%
All

Overview

Volume
15.52K
52 Week Range
$9.56 – $23.10
Float Shares
28.41M
% Held by Insiders
33.16%
% Held by Institutions
7.81%
RVOL
1.13x
Beta
0.07

Pipeline · 0 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
No pipeline trials tracked.

Catalyst news & presentations · 4

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: · 0 offerings/1y · 0 PIPEs
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

strong buy · target $45 (+360% upside) · 1 analysts
  • no recent rating changes

Competitors

  • none identified

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.